Kornimate/medical-research-clean huggingface dataset:
effects of liuzijue exercise versus tai chi chuan exercise in asthma

Conditions: Asthma

Summary: to analyze either liuzijue exercise or tai chi chuan exercise is effective in improving dyspnea index and pulmonary function in patients with asthma. in the general population, the rate of asthma is increasing day by day because of environmental and occupational risk factors which is becoming a burden. it causes shortness of breath, decreases lung volume, and disturbs quality of life. this study aims to improve dyspnea index, lung volume and quality of life of the patients with asthma.

liuzijue exercise is the most popular exercise in ancient chinese literature which is compiled by the chinese qigong management centre. liuzijue exercise includes inhalation and exhalation through various mouth patterns to manage and control the rise and fall of the breath in the body. it is performed by delivering 6 distinct sounds, ("xū", "hē", "hū", "sī", "chuī", and "xī") through termination along with comparing body activities. it is very helpful to improve pulmonary functions, exercise capacity, and quality of life of patients with pulmonary disease. liuzijue exercise takes on the backward abdominal breathing technique joined with physical exercises, which can practice the diaphragm and chest auxiliary respiratory muscles. hence, the patient's breathing time is extended, and the breathing profundity increments. to accomplish the reason for expanding the gas exchange rate of the lungs and enhancing the lung capacity. tai chi chuan is a traditional chinese exercise that is significant in improving the pulmonary functions of asthmatic patients. tai chi (10 forms of yang style ) significantly improves the exercise capacity of patients with lung disease. tai chi seems to have physiologic and psychosocial benefits and appears to be protected and viable in advancing balance control, adaptability, and cardiovascular fitness for older adults.

Eligibility criteria:
inclusion criteria: * diagnosed case of asthma for last 6 months * patients with mild to moderate asthma * on spirometry fev1/fvc ratio less than 70% * mrc- grade 2 and 3 exclusion criteria: * refusal to consent. * unstable vitals. * diagnosed with any lung disease. * uncontrolled hypertension. * diagnosed tumor. * patient with stroke and other neurological conditions. * patient with active tuberculosis or other infectious disease. * patients with history of heart failure or any other cardiovascular condition

Keywords: liuzijue exercise tai chi chuan exercise dyspnea index pulmonary function asthma
marijuana approach bias retraining and neural response in youth

Conditions: Alcohol Approach/Avoidance Task; Sham Approach/Avoidance Task

Summary: this study aims to determine if a marijuana (mj) approach avoidance task (aat) intervention reduces cannabis use compared to a control condition containing no active components of aat. adolescent heavy mj users (n=40, ages 16-21) will be randomly assigned to mj-aat (n=20) or control condition (mj-sham, n=20) for three weeks. the mj-aat includes six sessions designed to reduce action tendencies to approach marijuana. the mj-sham includes six mj-aat-sham conditions. substance use and cognitive assessment will identify changes in mj use patterns and mechanisms of treatment outcomes. additionally, using an functional magnetic resonance imaging marijuana cue reactivity task, we will determine differences in neural response in reward regions before and after 3 weeks of either aat or sham treatment.


Eligibility criteria:
inclusion criteria: * between age 16 and 21 * having \>50 lifetime marijuana use episodes and a pattern of at least weekly marijuana use for the past year (\>1+/week for 52 weeks) at study entry. exclusion criteria: * not having a parent to consent (for those under age 18) * prenatal alcohol (\>2 drinks on an occasion or \>4 drinks in a week) or any tobacco or illicit drug exposure * premature birth (\<34 weeks gestation), birth weight \<5 lbs, or other gestational or perinatal complications * history of a serious medical or neurological problems that could affect blood oxygen level dependent (bold) response, brain development, or study participation, including diabetes and recurrent migraine * current severe diagnostic and statistical manual of mental disorders (dsm-5) major axis i psychiatric disorder (i.e., exclude participants with bipolar disorder, psychotic disorder) * use of any illicit substance (e.g., cocaine, methamphetamines) other than alcohol or marijuana \> 100 times * history of major neurological disorder or head trauma (with loss of consciousness \>10 minutes) * history of learning disability, pervasive developmental disorder, or other condition requiring special education * current use of medications that affect cerebral blood flow * non-correctable visual or hearing problems * non-fluent in english * mri contraindications (e.g., braces, claustrophobia, irremovable metal implants or piercings) * pregnant on day of scan * intake of psychoactive medication as tested by urine drug screen.
comparison of 1,550 and 755 laser in a split-face trial

Conditions: Acne Scars - Mixed Atrophic and Hypertrophic

Summary: clinical trial comparing the 1,550-nanometer fractionated photothermolysis system laser to the 755 nanometer picosecond laser using a split-face (right-left) comparison. patients will receive laser treatments at week 0, week 4, and week 8. photographs will be taken prior to laser treatment at each visit, and at the week 24 follow-up visit. photographs will be reviewed by blinded assessors to rate each side of the face and change from baseline photos.

this is a clinical trial comparing the 1,550-nanometer fractionated photothermolysis system laser to the 755 nanometer picosecond laser using a split-face (right-left) comparison. both of these lasers are currently fda approved for acne scarring. approximately 18 subjects, men and women with fitzpatrick skin types i through v and facial acne scarring of grades iii-iv (moderate to severe) will be enrolled. both sides of the participants' face should have similar amount and severity of acne scarring. participants will be over 18 years old. patients have to be otherwise healthy without a history of skin cancer, keloidal scarring, localized or active infection, immunodeficiency disorders, and light sensitivity. patients have to be overall healthy without a history of skin cancer, keloidal scarring, localized or active infection, immunodeficiency disorders, and light sensitivity. per pi discretion, any serious medical condition that may interfere with the study. in addition, patients who have been taking isotretinoin for a period of 6 months before treatment will be excluded. patients will have photographs taken at every visit prior to the laser treatments at week 0, week 4, and week 8. photographs will also be taken at the week 24 follow-up visit. photos will then be assessed by qualified blinded reviewers for comparison.

Eligibility criteria:
inclusion criteria: * men and women with fitzpatrick skin types i through v and facial acne scarring of grades iii-iv (moderate to severe) will be enrolled. both sides of the participants' face should have similar amount and severity of acne scarring. participants will be over 18 years old. patients have to be otherwise healthy without a history of skin cancer, keloidal scarring, localized or active infection, immunodeficiency disorders, and light sensitivity. exclusion criteria: * patients have to be overall healthy without a history of skin cancer, keloidal scarring, localized or active infection, immunodeficiency disorders, and light sensitivity. per pi discretion, any serious medical condition that may interfere with the study. in addition, patients who have been taking isotretinoin for a period of 6 months before treatment will be excluded.
italian multicenter observational registry on takostubo syndrome

Conditions: Takotsubo Syndrome

Summary: takotsubo syndrome (tts) has recently been described as an acquired form of cardiomyopathy whose pathophysiology is not yet well understood and mainly affects postmenopausal women. tts or "broken heart" syndrome was first described in japan in 1991. the japanese term "tako-tsubo" means "polyp vessel" and describes the morphology of the left ventricular apex during systole in patients with this condition. the onset usually follows physical or emotional stress and mimics that of acute coronary syndrome (acs) with a parade of symptoms, including chest pain, dyspnea, syncope, and nausea. objective examination is often normal or otherwise nonspecific. ecg may document st-t changes while echocardiogram shows areas of altered ventricular kinetics. serum cardiac biomarkers may be increased. currently, the gold standard method for the diagnosis of tts is coronarography, which documents epicardial coronary arteries that are normal or free of critical lesions. it is estimated that more than 2.5% of patients with a suspected diagnosis of acs have tts, and this number is probably underestimated. although the prognosis of tts is generally considered favorable, during the acute phase these patients can develop potentially fatal complications such as ventricular arrhythmias, cardiogenic shock, and heart rupture. moreover, emerging scientific evidence sheds light on the need to adopt a dedicated diagnostic-therapeutic pathway for this type of patients. the exact pathophysiology of tts is still unknown and no large population studies or registries are currently available. therefore, the purpose of the study is to better characterize the profile of this disease through the creation of a large registry.


Eligibility criteria:
inclusion criteria: patients diagnosed with tts in accordance with the intertak diagnostic criteria. exclusion criteria: * age less than 18 years * myocarditis * acute coronary syndrome * myocardial infarction with non obstructive coronary arteries (minoca)

Keywords: takotsubo cardiomyopathy cardiogenic shock lvoto mitral regurgitation heart failure
study in patients with copd

Conditions: COPD

Summary: the purpose of this study is to determine the efficacy and safety of the investigational drug in the treatment of copd in comparison with a placebo.


Eligibility criteria:
inclusion criteria: * medical diagnosis of copd * current or prior history of cigarette smoking exclusion criteria: * medical diagnosis of asthma * chest x-ray (cxr) prior to day 1 diagnostic of significant disease other than copd * significant condition or disease other than copd

Keywords: chronic obstructive pulmonary disease copd formoterol formoterol fumarate
oral and gut microbiota changes during long-term fasting in humans

Conditions: Healthy; Periodontitis

Summary: the aim of this longitudinal trial is to investigate the effects of a 10±3-day fasting period in 30 subjects. changes in the oral and gut microbiota, halitosis, as well as inflammatory and antioxidative parameters and biomarkers of sulfur metabolism will be analysed.

fasting has been linked with changes in gut microbiota as part of the physiological adaptation. furthermore, associations have been described between oral disease and nutrition (diet rich in carbohydrates). the aim of the present longitudinal clinical study is to explore the effect of a 10±3-day fasting period on the oral and gut microbiota. 30 systemically healthy subjects attending the buchinger wilhelmi clinics for fasting, will participate. changes in oral microbiota will be assessed in plaque and saliva samples and a number of inflammatory markers will be analyzed in gingival crevicular fluid (gcf) and blood obtained before, during and after the fasting period. the changes in the oral microbiota will be associated to the composition of the gut microbiota. changes in periodontal parameters and halitosis related to the fasting period will be further evaluated. given the known association between sulfur metabolism and the redox status, parameters from the antioxidant status and oxidative damages will also be assessed.

Eligibility criteria:
inclusion criteria: * both subjects with periodontitis and healthy periodontium will be included. * signed informed consent exclusion criteria: * not able to sign the informed consent * diagnosticated with cachexia, anorexia, nervosa, advanced kidney, liver or cerebrovascular insufficiency * smoking * the intake of antibiotics within the last 8 weeks, as well as the intake of probiotics within the last 4 weeks * periodontal treatment in the last 6 months * chronic manifest psychical and psychiatric diseases * participation in another study * pregnancy or breastfeeding

Keywords: oral microbiota intestinal microbiota inflammatory status redox status sulfur metabolism halitosis
asian women's action in resilience and empowerment

Conditions: Mental Health Disorder

Summary: our objective for this r34 is to develop gender/culture specific and trauma informed group psychotherapy intervention designed to treat chinese-, korean-, and vietnamese-american young women with histories of interpersonal violence trauma. the intervention is called asian women's action for resilience and empowerment (aware).

recent epidemiological studies document two emerging public health problems among asian-pacific islander (api) women in the us: 1. a growing incidence of hiv/aids. although the prevalence of hiv/aids among apis is low compared to those among blacks, whites, and hispanics, hiv infection among apis significantly increased (44%) between 2004 and 2007. additionally, 75% of hiv transmission among api women is through heterosexual intercourse, which is substantially higher than percentages among other racial/ethnic groups of women. 2. poor mental health functioning exhibited by completed suicide rates. young api women (ages 15 to 34) have not only the highest rates of completed suicide compared to other women of the same age in the us, but also experienced the largest growth in rates of suicide over the past decade. our preliminary studies using both quantitative and qualitative methods found strong links between past trauma and poor sexual and mental health outcomes. for api women, reporting a history of forced sex was associated with higher odds of severe depression, substance use, getting pregnant, and hiv risk behaviors compared to api women who did not report a history of forced sex. api women continue to be vulnerable given their lower rates of hiv testing, lower mental health utilization, and premature dropout rates in mental health treatment compared to other racial groups. so far, no existing intervention targets both sexual health and mental health problems among api women. specifically, this study builds upon data on api women from prior nimh-funded work as the foundation for our intervention.

Eligibility criteria:
inclusion criteria: * self-identify as female; * are unmarried; * are between the ages 18 and 35; * are of chinese, korean, and/or vietnamese descent; * are 1.5 (immigrated to the us before the age of 18) or 2nd (us-born children of 1st generation immigrants) generation; * are fluent in english; * have a mobile phone with text messaging; * have had penile-vaginal intercourse in their lifetime; * have a history of exposure to at least one of five selected criteria in the traumatic life events questionnaire (tleq). these criteria include: beaten by stranger, death threat, childhood physical abuse, family violence, and partner physical assault; exclusion criteria: * at current significant risk of homicidal or suicidal behavior * having symptoms of psychosis; * have previously experienced natural disasters or other non-violent trauma; * are of mixed race other than korean-, chinese-, or vietnamese-americans;

Keywords: mental health suicide sexual risk behaviors
study to evaluate immunogenicity and safety of glaxosmithkline (gsk) biologicals' quadrivalent influenza vaccine gsk2282512a when administered to children 6 to 35 months of age

Conditions: Influenza

Summary: the purpose of this study is to investigate the immunogenicity, reactogenicity and safety of the new influenza vaccine gsk2282512a (flu-q-qiv) and compare its activity to the marketed vaccine fluarix® (tiv) in young children 6 to 35 months of age.

the subjects will be randomized (1:1) in the 2 treatment groups to explore responses to vaccination in a sub-group analysis based on age (6 to 17 months, 18 to 35 months).

Eligibility criteria:
inclusion criteria: * subject's parent(s)/legally acceptable representative(s) \[lar(s)\] who, in the opinion of the investigator, can and will comply with the requirements of the protocol. * a male or female between, and including, 6 and 35 months of age at the time of the first vaccination. * written informed consent obtained from the parent(s)/lar(s) of the subject. * subjects in stable health as determined by the investigator's clinical examination and assessment of subject's medical history. * subjects are eligible regardless of history of administration of influenza vaccine in a previous season. exclusion criteria: * use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period. routine registered childhood vaccinations are permitted. * child in care. * prior receipt of any seasonal or pandemic influenza vaccine within six months preceding the first dose of study vaccine, or planned use during the study period. * chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dosed. * administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period. * history of guillain-barré syndrome within six weeks of receipt of prior influenza vaccine. * any known or suspected allergy to any constituent of influenza vaccines; a history of anaphylactic-type reaction to consumption of eggs; or a history of severe adverse reaction to a previous influenza vaccine. * acute disease and/or fever at the time of enrolment. * any significant disorder of coagulation or treatment with warfarin derivatives or heparin. * any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. * any other condition which, in the opinion of the investigator, prevents the subject from participating in the study.

Keywords: immunogenicity children safety seasonal influenza fluarix
a multicenter, phase 3, randomized trial of sequencial chemoradiotherapy with or without toripalimab (pd-1 antibody) in newly diagnosed early-stage extranodal natural killer/t cell lymphoma, nasal type (enktl)

Conditions: NK/T Cell Lymphoma Nos

Summary: the purpose of this randomized, multi-center,phase ⅲ clinical trail is to compare the safety and efficacy of sequencial chemoradiotherapy with or without toripalimab (pd-1 antibody) for newly diagnosed early-stage extranodal natural killer/t-cell lymphoma, nasal type (enktl)


Eligibility criteria:
inclusion criteria: * biopsy proved extranodal natural killer/t-cell lymphoma, nasal type; * newly diagnosed stage i/ii patients; * at least one evaluable lesion； * ecog ps 0-2; * 18-75 years; without other malignancy; * proper functioning of the major organs. exclusion criteria: * hemophagocytic syndrome or aggressive nk cell leukemia; * involvement of central nervous system; * previously received treatment of chemotherapy, radiotherapy, immunotherapy or biotherapy for lymphoma；
a trial of vitamin d therapy in patients with heart failure

Conditions: Heart Failure

Summary: the purpose of this study is to determine if vitamin d will improve physical performance in older adults with heart failure.

the study is designed as a short pilot study which will assess safety and efficacy of high dose vitamin d therapy in a heart failure population. a 6 month randomized double blind placebo-controlled trial of 50,000 units of oral vitamin d3(cholecalciferol) weekly plus 800 calcium daily vs. weekly placebo plus 800 calcium alone in 64 heart failure (hf) patients \> 50 years old. this design was chosen over a cross-over design due to the long wash-out period for vitamin d.

Eligibility criteria:
inclusion criteria: * new york heart association (nyha) class ii-iv * able to walk * serum 25ohd level 37.5 ng/ml or less * fully titrated on heart failure medications exclusion criteria: * osteoporosis * primary hyperparathyroidism or hypercalcemia. * nephrolithiasis * hemo or peritoneal dialysis and/or creatinine of \> 2.5 * current use of daily vitamin d greater than 400 iu, corticosteroids, parathyroid hormone (pth), androgen or estrogen * current illicit drug user or \> 3 alcoholic drinks a day * metastatic or advanced cancer * myocardial infarction in the preceding 6 months * medications which can lower vitamin d levels or bioavailability

Keywords: aerobic capacity strength
omega-3 supplementation and attention-deficit-hyperactivity disorder (adhd)

Conditions: Attention Deficit Hyperactivity Disorder

Summary: it is assumed that only 1/5 of children diagnosed with attention-deficit-hyperactivity disorder (adhd) are treated. new treatment modalities are urgently needed. omega-3 fatty acids have been used in this setting, yet results are conflicting. the parent omega-3 fatty acid alpha-linolenic acid (ala) has only been used in one trial. 40 children diagnosed with adhd will be randomized to consume either ala or placebo for two months. baseline and end assessments will include adhd-related questionnaires and a computerized test. the investigators hypothesize that ala supplementation will prove beneficial for children with adhd.


Eligibility criteria:
inclusion criteria: * adhd diagnosis * informed consent exclusion criteria: * refusal of any testing * any comorbidities * any medication or supplement use

Keywords: adhd methylphenidate omega-3
dietary determinants in patients with nonalcoholic fatty liver disease (nafld)

Conditions: Dietary Intake; NAFLD

Summary: patients with nafld and matched controls will be asked about their demographic status, and their previous year dietary intakes using a validated ffq.


Eligibility criteria:
inclusion criteria: * age more than 18 * nafld was diagnosed by fibroscan and other hepatic disorders ruled out exclusion criteria: * not completing more than 10% of the questionnaire